T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

U.K.-based biotechnology company T-Therapeutics has raised $133 million in Series B financing to advance its pipeline of T-cell receptor (TCR) therapies for cancer and autoimmune diseases. Co-led by Advent Life Sciences and the British Business Bank, the funding round drew broad backing from major pharmaceutical investment arms—including Eli Lilly, Johnson & Johnson's JJDC, Merck KGaA's M Ventures, and Sanofi Ventures—alongside a syndicate of venture capital investors.

Series B funding details

• ▪U.K.-based biotechnology company T-Therapeutics secured $133 million in Series B venture capital financing as part of its ongoing capital raise for therapeutic development
• ▪The Series B round for T-Therapeutics included participation from corporate venture entities JJDC, M Ventures, and Sanofi Ventures, alongside Eli Lilly, Samsara BioCapital, Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Tencent, and BGF
• ▪Advent Life Sciences and the British Business Bank co-led the $133 million Series B financing round for T-Therapeutics

Therapeutic focus and platform

• ▪T-Therapeutics directs its drug development platform toward treating indications in both oncology and autoimmune disease
• ▪T-Therapeutics specializes in the research and development of T-cell therapies